Reuters logo
BRIEF-Lysogene selects Brammer Bio to produce GM1 gangliosidosis gene therapy product
May 24, 2017 / 5:47 AM / 6 months ago

BRIEF-Lysogene selects Brammer Bio to produce GM1 gangliosidosis gene therapy product

May 24 (Reuters) - LYSOGENE SA:

* LYSOGENE SELECTS BRAMMER BIO TO PRODUCE GM1 GANGLIOSIDOSIS GENE THERAPY PRODUCT

* HAS ENTERED INTO A STRATEGIC MANUFACTURING AGREEMENT WITH BRAMMER BIO, A BEST-IN-CLASS VIRAL GENE AND CELL THERAPY MANUFACTURER

* STRATEGIC MANUFACTURING AGREEMENT COVERS LYSOGENE‘S AAVRH10-BASED GENE THERAPY TREATMENT

* LYSOGENE SA -PRE-CLINICAL DATA IN ANIMAL MODELS OF GM1 SHOW LYS-GM101 TREATMENT DELIVERS FUNCTIONAL GENE ENCODING ΒGAL ENZYME RESULTING IN REDUCTION OF GM1 GANGLIOSIDES AND TRANSFORMS ANIMAL PHENOTYPE

* THESE STUDIES WILL SUPPORT AN INVESTIGATIONAL NEW DRUG APPLICATION AND LAUNCH OF PHASE I CLINICAL TRIAL, EXPECTED TO LAUNCH IN 2019 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below